Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Return on Equity (2018 - 2025)

Neurogene's Return on Equity history spans 6 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Equity fell 1.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.35%, down 1.0%, while the annual FY2025 figure was 0.32%, 1.0% down from the prior year.
  • Return on Equity reached 0.35% in Q4 2025 per NGNE's latest filing, down from 0.32% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.23% in Q3 2023 to a low of 37.4% in Q4 2023.
  • Average Return on Equity over 3 years is 3.44%, with a median of 0.33% recorded in 2025.
  • The largest YoY upside for Return on Equity was 3707bps in 2024 against a maximum downside of -70bps in 2024.
  • A 3-year view of Return on Equity shows it stood at 37.4% in 2023, then surged by 99bps to 0.33% in 2024, then decreased by -4bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Return on Equity are 0.35% (Q4 2025), 0.32% (Q3 2025), and 0.3% (Q2 2025).